Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.56 |
| ▸ | POLG | P54098 | 2/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.55 |
| ▸ | PNP | P00491 | 3/20 | 0.54 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.53 |
| ▸ | KRAS | P01116 | 2/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.50 |
| ▸ | POLA1 | P09884 | 1/20 | 0.48 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dideoxy Guanosine Triphosphate SCHEMBL80109 | 1.00 | POLB (0.60) | POLBP2RY2P2RY4P2RY6POLG | |
| Dideoxy Guanosine Triphosphate SCHEMBL24370775 | 1.00 | POLB (0.60) | POLBP2RY2P2RY4P2RY6POLG | |
| Dideoxy Guanosine Triphosphate SCHEMBL25720613 | 1.00 | POLB (0.60) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL18095578 | 1.00 | POLB (0.60) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL4968018 | 0.99 | POLB (0.61) | POLBP2RY2P2RY4P2RY6POLG | |
| Dideoxy Guanosine Triphosphate SCHEMBL6915085 | 0.94 | POLB (0.54) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL26855308 | 0.93 | POLB (0.54) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL27378463 | 0.93 | POLB (0.54) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL19662102 | 0.93 | POLB (0.66) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL1762945 | 0.92 | POLB (0.57) | POLBP2RY2P2RY4P2RY6POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4677111-A2 | SYSTEMS, METHODS, AND COMPOSITIONS FOR SEQUENCING | Ultima Genomics, Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| WO-2024186844-A2 | SYSTEMS, METHODS, AND COMPOSITIONS FOR SEQUENCING | ULTIMA GENOMICS, INC. (US) | 2024-09-12 | — | — | WO | claimed |
| US-12624392-B2 | Molecular array generation using photoresist | 10X GENOMICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12565641-B2 | Engineered terminal deoxynucleotidyl transferase variants | CODEXIS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4677111-A2 | SYSTEMS, METHODS, AND COMPOSITIONS FOR SEQUENCING | Ultima Genomics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4602159-A2 | ENGINEERED TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE VARIANTS | Codexis, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-4481059-A2 | MOLECULAR ARRAY GENERATION USING PHOTORESIST | 10x Genomics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-4271511-B1 | MOLECULAR ARRAY GENERATION USING PHOTORESIST | 10X GENOMICS INC (US) | 2024-10-09 | — | — | EP | disclosed |
| WO-2024186844-A2 | SYSTEMS, METHODS, AND COMPOSITIONS FOR SEQUENCING | ULTIMA GENOMICS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| EP-4416276-A1 | ENGINEERED TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE VARIANTS | Codexis, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| US-12012594-B2 | Methods and compositions for long-range haplotype phasing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-18 | — | — | US | disclosed |
| US-20230074770-A1 | Methods and Compositions for Long-Range Haplotype Phasing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-09 | — | — | US | disclosed |
| WO-2022197727-A9 | GENERATION OF NOVEL CRISPR GENOME EDITING AGENTS USING COMBINATORIAL CHEMISTRY | DUKE UNIVERSITY (US) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022197727-A1 | GENERATION OF NOVEL CRISPR GENOME EDITING AGENTS USING COMBINATORIAL CHEMISTRY | DUKE UNIVERSITY (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20220228210-A1 | MOLECULAR ARRAY GENERATION USING PHOTORESIST | 10X GENOMICS, INC. | 2022-07-21 | — | — | US | disclosed |
| WO-2022147140-A1 | MOLECULAR ARRAY GENERATION USING PHOTORESIST | 10X GENOMICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-11326159-B2 | Methods and compositions for long-range haplotype phasing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-10 | — | — | US | disclosed |
| CN-114250301-A | Method for analyzing somatic mobile factors and use thereof | 嘉普科德基因组学公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-114250274-A | Amplification of primers with limited nucleotide composition | 阿提拉生物系统公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-114196739-A | Formula and application of nucleic acid mass spectrum detection reagent | 新起点生物科技(苏州)有限公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565641-B2 | Engineered terminal deoxynucleotidyl transferase variants | DNTT, RNGTT, POLM | POLB 13/4885P2RY2 1473/4885P2RY4 1120/4885 |
| US-12624392-B2 | Molecular array generation using photoresist | POLL, LIG4, LIG3 | POLB 20/4885P2RY2 1016/4885P2RY4 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.